All lobbying filings

Harmony Biosciences

Harmony Biosciences filed a Q3 report for Harmony Biosciences on October 19, 2025.

Lobbying for Harmony Biosciences · pharmaceuticals

As filed: HARMONY BIOSCIENCES for HARMONY BIOSCIENCES.

All filings by Harmony Biosciences · Everything Harmony Biosciences has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 19, 2025

Expenses

$180,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Pennsylvania

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act

Bills named in this filing 2

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
H.R. 1672
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.